Notch and Gamma-Secretase Modulators for Parkinson's Disease

Overview

Overview

This page catalogs biotechnology and pharmaceutical companies developing therapeutics targeting the Notch signaling pathway and gamma-secretase for Parkinson's disease. The Notch pathway has emerged as a critical regulator of neurodegenerative processes through its roles in neural development, synaptic plasticity, and cellular stress responses["@lasky2020"]. In PD, Notch signaling intersects with key pathological processes including alpha-synuclein aggregation, dopaminergic neuron degeneration, neuroinflammation, and mitochondrial dysfunction["@song2019"].

While gamma-secretase inhibitors have shown preclinical promise for PD, selective Notch modulation remains a key challenge due to the pathway's pleiotropic functions throughout the body["@kelleher2015"].

Scientific Background

Notch Signaling in Parkinson's Disease

The Notch family consists of four receptors (Notch1-4) and multiple ligands (Jagged1, Jagged2, DLL1, DLL3, DLL4). In PD, Notch signaling plays several important roles[@liu2018a]:

• Dopaminergic neuron development and survival: Notch regulates dopaminergic neuron specification during embryogenesis
• Protein quality control: Notch signaling modulates protein quality control pathways including the ubiquitin-proteasome system and autophagy-lysosomal pathways
• Neuroinflammation: Notch-NF-κB cross-talk represents a key intersection between neuroinflammation and Notch signaling in PD
• Mitochondrial function: Notch signaling influences mitochondrial dynamics, fission/fusion, and mitophagy

Gamma-Secretase as a Therapeutic Target

Gamma-secretase is a proteolytic enzyme complex that cleaves Notch receptors during canonical signaling. While gamma-secretase inhibitors (GSIs) have shown neuroprotective effects in PD models[@pan2020], they face significant challenges[@bittner2016]:

• Pleiotropic functions: Gamma-secretase processes over 100 substrates beyond Notch
• Side effects: Complete inhibition causes gastrointestinal toxicity and hematological effects
• Therapeutic window: Selective targeting of Notch over other substrates remains challenging

Companies and Programs

Large Pharmaceutical Companies

Merck & Co.

Status: Research Stage Program: MK-0752 and related Notch inhibitors

Merck has developed MK-0752, a potent gamma-secretase inhibitor that has been evaluated in clinical trials for oncology. Research has explored repurposing MK-0752 and related compounds for neurodegenerative diseases including PD and Alzheimer's disease.

Mechanism: Gamma-secretase inhibition reduces Notch signaling, which is dysregulated in PD patient neurons. Preclinical studies suggest reduced Notch activity may protect dopaminergic neurons from neurotoxin-induced damage.

Development Status: Preclinical/Research stage for PD; no active clinical trials in PD as of 2024.

Key References:

• MK-0752 has been studied in Phase 1 clinical trials for cancer (not PD)
• Preclinical PD models show neuroprotective effects of GSI treatment

Bristol-Myers Squibb

Status: Research Stage Program: Notch pathway modulators

Bristol-Myers Squibb has explored Notch signaling modulators in the context of cancer and inflammatory diseases. While not actively developing PD-specific programs, the company has contributed to understanding Notch biology that informs neurodegeneration research.

Relevant Research: BMS-906039 is a pan-Notch inhibitor that has been investigated in oncology. While not in active PD development, the compound has been used in research to understand Notch-dopaminergic neuron interactions.

Yuhan Corporation

Status: Phase 1 (AD, potential PD) Program: YH-4001 - Gamma-secretase modulator

Yuhan Corporation is developing YH-4001, a gamma-secretase modulator targeting APP processing in Alzheimer's disease. While currently in development for AD, the modulator approach may have relevance for PD in the future.

Mechanism: Modulation (rather than complete inhibition) of gamma-secretase activity shifts processing away from amyloid-beta peptide production while preserving essential Notch signaling and other vital functions. This selective modulation approach may provide a wider therapeutic window.

Clinical Status: Phase 1 clinical trials in Alzheimer's disease (2024).

See also: [Yuhan Corporation](/companies/yuhan-corporation) - for complete company profile

Biotechnology Companies

Denali Therapeutics

Status: Preclinical/Research Program: LRRK2 inhibitors with Notch considerations

While Denali's primary focus is on LRRK2 inhibition for PD, their research program considers pathway interactions between LRRK2 and Notch signaling. Studies have shown that LRRK2 kinase activity can affect Notch processing, providing potential combination opportunities.

Development Status: DNL151 (BIIB122) in Phase 2b for PD; early-stage programs explore pathway interactions.

See also: [Denali Therapeutics](/companies/denali) - for complete company profile

Prothena Corporation

Status: Research Program: Protein clearance pathways

Prothena has developed expertise in protein clearance mechanisms relevant to neurodegenerative diseases. While their lead program (prasinezumab) targets alpha-synuclein, their research platform encompasses autophagy and protein quality control pathways that intersect with Notch signaling.

Relevant Research: Understanding of how Notch modulates autophagy-lysosomal pathways may inform future combination approaches.

Academic and Research Programs

University Research Programs

Multiple academic centers have conducted preclinical research on Notch/gamma-secretase modulators for PD:

| Institution | Focus | Status |
|-------------|-------|--------|
| Johns Hopkins University | GSI-IX neuroprotection in MPTP model | Preclinical |
| Columbia University | Notch-alpha-syn interactions | Preclinical |
| University of Pennsylvania | iPSC models of Notch dysregulation | Research |

Pipeline Overview

| Company | Drug/Mechanism | Indication | Stage | Notes |
|---------|----------------|------------|-------|-------|
| Merck | MK-0752 (GSI) | PD | Research | Repurposing potential |
| Yuhan | YH-4001 (GSM) | AD→PD potential | Phase 1 | Modulator approach |
| Denali | LRRK2 inhibitors | PD | Phase 2b | Pathway interactions |
| Prothena | Protein clearance | PD | Phase 2 | Autophagy modulators |

GSI = Gamma-Secretase Inhibitor GSM = Gamma-Secretase Modulator

Challenges in Developing Notch-Targeted PD Therapies

Pathway Complexity

The Notch pathway presents significant therapeutic challenges[@kelleher2015]:

• Pleiotropy: Notch has multiple functions throughout the body
• Compensation: Receptor redundancy may limit single-target approaches
• Timing: Critical windows for intervention during disease progression

Safety Considerations

Complete Notch inhibition may cause[@bittner2016]:

• Gastrointestinal toxicity (notch inhibition affects gut epithelium)
• Hematological effects (impaired lymphocyte development)
• Vascular changes (altered angiogenesis)

Therapeutic Windows

Optimal timing for Notch-targeted interventions:

• Pre-symptomatic: Prevent degeneration through neuroprotection
• Early disease: Modify disease progression
• Late disease: May have limited efficacy

Future Directions

Novel Therapeutic Approaches

Emerging strategies for Notch-targeted PD therapy:

• Notch-specific antibodies: Targeting specific Notch receptors (Notch1 vs Notch2)
• Notch modulators: Allosteric modulators with enhanced selectivity
• Combination therapy: Notch modulation with other disease-modifying approaches
• Gene therapy: Viral vector-mediated Notch modulation

Biomarker Development

Critical needs for clinical development:

• Soluble Notch receptors in cerebrospinal fluid
• Notch target gene expression in peripheral blood mononuclear cells
• NICD levels as a marker of pathway activation
• Standardized assay protocols for clinical use

Personalized Medicine Approaches

Future directions include:

• Stratification based on Notch pathway activity
• Individualized timing of intervention
• Combination of biomarker assessment with genetic profiling

Cross-References

• [Notch Signaling in Parkinson's Disease](/mechanisms/notch-signaling-parkinsons) - Mechanism page
• [Notch Signaling Pathway in Neurodegeneration](/mechanisms/notch-signaling-pathway) - General mechanism
• [NOTCH1 Gene](/genes/notch1) - Gene page
• [NOTCH2 Gene](/genes/notch2) - Gene page
• [Alpha-Synuclein Aggregation Pathway](/proteins/alpha-synuclein)-aggregation-pathway) - Related mechanism
• [Parkinson's Disease](/diseases/parkinsons-disease) - Disease overview

External Links

• [Nature Reviews Drug Discovery - Gamma-secretase challenges](https://www.nature.com/nrd)
• [Nature Reviews Neurology - Notch targeting](https://www.nature.com/nrneurol)
• [PubMed - Notch signaling PD](https://pubmed.ncbi.nlm.nih.gov/?term=Notch+Parkinson)
• [ClinicalTrials.gov](https://clinicaltrials.gov)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Notch and Gamma-Secretase Modulators for Parkinson's Disease discovered through SciDEX knowledge graph analysis: